Phase 4 N=1 Diltiazem in Jervell and Lange-Nielsen Syndrome
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Phase 3 N=31 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
Phase 1 N=12 Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
Rett Syndrome
Primary: Adverse Events — 4; 4; 2; 17 Adverse events
Phase 4 N=36 Oral Contraceptives in the Metabolic Syndrome
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L
N/A N=1,504 Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)
Restless Legs Syndrome
Primary: Summary of Change From Baseline in Total Sum of McGill Pain Questionnaire to Visit 3 — -14.48 Scores on scale
Phase 2 N=19 Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Endocrine Disease · Diabetes
Primary: Change in Insulin Sensitivity Index — 1.49; 1.41 min-1·μU·ml-1 — p=0.60
Phase 3 N=40 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
Phase 4 N=15 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
Treatment Resistant Nephrotic Syndrome
Primary: Significant Reduction in Proteinuria to Remission Levels During the Treatment Period (Includes Complete and Partial Remission, as Defined in the Outcome Measure…
N/A N=51 Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
Metabolic Syndrome · Dyslipidemia · Obesity, Abdominal
Primary: Total Cholesterol Levels — 5.8; 5.9 mmol/L
N/A N=10 Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
Tourette Syndrome
Primary: Yale Global Tic Severity Scale — 64.40; 26.40 units on a scale
Phase 4 N=39 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Down Syndrome
Primary: Changes in Neuropsychological Measures From Baseline to End of Study — -0.22; -0.84; 0.56; 0 units on a scale — p=0.403
Phase 4 N=41 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
Turner Syndrome · Hypogonadism · Premature Ovarian Failure
Primary: Change in Weight From Baseline at 12 Months — 1.1; 1.9 kilograms
N/A N=31 Study Protocol for CTS and Keyboard Controlled Randomized Trial
Carpal Tunnel Syndrome
Primary: Length of Time Typing QWERTY Prior to Experiencing Symptoms of CTS (Carpal Tunnel Syndrome) — 71.063 minutes
N/A N=60 Evaluation of Group Lifestyle Balance Maintenance Strategies
Diabetes
Primary: Change in Weight — 2.1; 0.2 pounds